Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.
Dowall, S. D., Graham, V. A., Corbin-Lickfett, K., Empig, C., Schlunegger, K., Bruce, C. B., … Hewson, R. (2015). Effective binding of a phosphatidylserine-targeting antibody to ebola virus infected cells and purified virions. Journal of Immunology Research, 2015. https://doi.org/10.1155/2015/347903